Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Eric Furman
Federal Circuit Affirms Invalidation of Patent for Lack of Enablement of Claims Directed to a Method of Treating a Patient With “A Unit Dosage” in Wyeth LLC v. Astrazeneca Pharmaceuticals LP.
Skip to content IP + Technology Law Home » News & Insights » Blogs » Biotechnology | Share Related Links Patent Strategy & Prosecution U.S. Patent Prosecution Biotech Chemical, Industrial & Materials Pharmaceuticals
Life Science Update | April 2026
One Battle After Another: Broad Institute Wins at PTAB in CRISPR Dispute Eric Furman, Ph.D. & Alistair J. McIntyre Interference proceedings, though increasingly rare, are heavily evidence-based and determine which party is the first inventor when two or more applicants claim the same patentable invention. Sometimes, an inventor’s own documents can be damaging to a claim of prior invention.
One Battle After Another: Broad Institute Wins at PTAB in CRISPR Dispute
Key Takeaways: Interference proceedings, though increasingly rare, are heavily evidence-based and determine which party is the first inventor when two or more applicants claim the same patentable invention. Sometimes, an inventor’s own documents can be damaging to a claim of prior invention.
Purdue Pharma’s $7.4 Billion Chapter 11 Plan Formally Approved | JD Supra
A federal bankruptcy court on November 18 formally approved Purdue’s $7.4 billion Chapter 11 plan to settle thousands of opioid-related lawsuits. The plan requires (1) a $6.5 billion contribution from the Sackler family members who own Purdue and (2) a $900 million contribution from Purdue itself.
Executive Order 14297 and the Global Drug Market: Policy, Pricing, and Uncertainty | JD Supra
On May 12, 2025, President Trump issued Executive Order 14297[1] targeting prescription drug prices in America. The stated purpose of this order is to combat high drug prices in the United States, bringing the prices Americans pay for drugs more in line with prices in the global marketplace.
FDA Publishes Case Studies and User Guide for Rare Disease Drug Developers | JD Supra
Drug development programs face unique challenges in demonstrating the safety and effectiveness of drugs for treating rare diseases.
CDRH Announces Pilot Program to Improve Recall Communication | JD Supra
On November 21, 2024, the FDA’s Center for Devices and Radiological Health (CDRH) announced a pilot communications program for improving the timeliness for communicating high-risk recalls.[1] The CDRH intends for the pilot program to provide early alerts of high-risk device removal or corrections related to a subset of device categories within the CDRH’s purview, including cardiovascular, gastrorenal, general hospital, obstetrics and gynecology, and urology devices.[2] No changes are being...
Senate Seeks to Reduce Biosimilar Prices by “Pruning” “Patent Thickets”
On July 10, the Senate unanimously passed the Affordable Prescriptions for Patients Act of 2023 (S.150), which seeks to increase competition and lower drug prices by imposing limits on patent litigation related to biological products.[1] The bill attempts to target “patent thickets” or the large patent portfolios companies create with significantly overlapping patent rights seen by lawmakers as obstacles to competitors entering the market.
FDA Issues Final Rule on Laboratory-Developed Tests | JD Supra
[1] FDA Takes Action Aimed at Helping to Ensure the Safety and Effectiveness of Laboratory Developed Tests, FDA (April 29, 2024) (https://www.fda.gov/news-events/press-announcements/fda-takes-action-aimed-helping-ensure-safety-and-effectiveness-laboratory-developed-tests). [3] Medical Devices: Laboratory Developed Tests.
FDA Issues Final Rule on Laboratory-Developed Tests
On April 29, 2023, the FDA announced a final rule on regulation of laboratory developed tests (LDTs).[1] The rule explicitly categorizes in vitro diagnostic products (IVDs) intended for clinical use as medical devices, which are within the purview of the FDA.[2] The final rule will publish on May 6, 2024.[3] Until then, the unpublished version is available.
USPTO Says Wands Still Controls Enablement Analysis Post-Amgen | JD Supra
On January 9, 2024, the USPTO published guidelines for its patent examiners when evaluating compliance with the enablement requirement in light of the U.S. Supreme Court’s recent decision in Amgen Inc. et al. v. Sanofi et al., 143 S. Ct. 1243 (2023). In Amgen, the Supreme Court unanimously held that claims drawn to a genus of monoclonal antibodies, which were functionally claimed, were invalid due to a lack of enablement.
USPTO Says Wands Still Controls Enablement Analysis Post-Amgen
On January 9, 2024, the USPTO published guidelines for its patent examiners when evaluating compliance with the enablement requirement in light of the U.S. Supreme Court’s recent decision in Amgen Inc. et al. v. Sanofi et al., 143 S. Ct. 1243 (2023). In Amgen, the Supreme Court unanimously held that claims drawn to a genus of monoclonal antibodies, which were functionally claimed, were invalid due to a lack of enablement.
Merck Sues Federal Government Over Medicare Drug Price Negotiation Program | JD Supra
On June 6, 2023, Merck & Co. filed a lawsuit against the U.S. government in federal court over the Inflation Reduction Act (IRA)’s Medicare drug price negotiation program, which allows Medicare to directly negotiate prices with drugmakers. The suit is the first attempt by a pharmaceutical company to challenge the IRA’s Medicare drug price negotiation program.
Merck Sues Federal Government Over Medicare Drug Price Negotiation Program
On June 6, 2023, Merck & Co. filed a lawsuit against the U.S. government in federal court over the Inflation Reduction Act (IRA)’s Medicare drug price negotiation program, which allows Medicare to directly negotiate prices with drugmakers. The suit is the first attempt by a pharmaceutical company to challenge the IRA’s Medicare drug price negotiation program.
Recent Update on Patent Trial Practice Guide | JD Supra
JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations. This Privacy Policy describes how JD Supra, LLC ("JD Supra" or "we," "us," or "our") collects, uses and shares personal data collected from visitors to our website (located at www.jdsupra.com) (our "Website") who view only publicly-available content as well as subscribers to our services (such as our email digests or author tools)(our "Services").
Bayh-Dole Act Revisions | JD Supra
JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations. This Privacy Policy describes how JD Supra, LLC ("JD Supra" or "we," "us," or "our") collects, uses and shares personal data collected from visitors to our website (located at www.jdsupra.com) (our "Website") who view only publicly-available content as well as subscribers to our services (such as our email digests or author tools)(our "Services").
Cannabis Considerations: Protecting your Cannabis Innovation | JD Supra
Early protection of intellectual property is a critical component in any business’s efforts to secure a competitive advantage in the marketplace. In the cannabis space, efforts to secure IP rights may be influenced by conflicting federal and state regulations. Despite increasing state regulation and legalization, cannabis remains a Schedule I drug under the Controlled Substances Act, and possession of cannabis is prohibited by federal law.
Lundbeck to Acquire Prexton Therapeutics for $1.1 billion | JD Supra
Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra: Already signed up? Log in here By using the service, you signify your acceptance of JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources.
Pfizer Accuses J&J of Anticompetitive Business Practices over Remicade Biosimilar
Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra: Already signed up? Log in here By using the service, you signify your acceptance of JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources.
Pfizer Accuses J&J of Anticompetitive Business Practices over Remicade Biosimilar
In a recent development with the ongoing complex litigation involving Janssen Biotech’s arthritis biologic medicine Remicade (infliximab) and Celltrion’s biosimilar,[1] Celltrion’s partner Pfizer has filed a suit against Janssen’s parent company Johnson & Johnson (J&J) in the Eastern District of Pennsylvania alleging that through anticompetitive pricing and exclusionary contracts with insurers and hospitals, J&J sought to preserve a monopoly over its sale of Remicade.[2] Pfizer alleges that...
Sovereign Immunity and Inter Partes Review
Sovereign immunity refers to the doctrine that the government cannot be sued without its consent. Specifically, the 11th Amendment precludes federal courts from exercising jurisdiction over states in suits brought by private citizens or subjects of a foreign state. “Sovereigns” include federal and state governments under the 11th Amendment, as well as, Native American Tribes under treaties.
FDA re-approves Mylotarg® antibody-drug conjugate seven years after it had been withdrawn from the market
Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra: Already signed up? Log in here By using the service, you signify your acceptance of JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources.
Doctrine of Equivalents under Enzo Biochem Inc. v. Applera Corp.
Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra: Already signed up? Log in here By using the service, you signify your acceptance of JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources.
In Helsinn Healthcare, the Federal Circuit Offers Guidance on the On-Sale Bar under the AIA
Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra: Already signed up? Log in here By using the service, you signify your acceptance of JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Eric
Contact Eric, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack